Edition:
India

Exelixis Inc (EXEL.OQ)

EXEL.OQ on NASDAQ Stock Exchange Global Select Market

16.82USD
21 Oct 2019
Change (% chg)

-- (--)
Prev Close
$16.82
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
747,747
52-wk High
$25.31
52-wk Low
$13.43

Latest Key Developments (Source: Significant Developments)

Exelixis - FDA Website Indicates That An ANDA Was Submitted To FDA For Cabometyx(Reg) Tablets
Friday, 27 Sep 2019 

Sept 26 (Reuters) - Exelixis Inc ::EXELIXIS - FDA WEBSITE INDICATES THAT AN ANDA WAS SUBMITTED TO FDA ON AUG. 16, FOR GENERIC VERSION OF CO'S CABOMETYX(REG) TABLETS (20 MG/40 MG/60 MG).EXELIXIS INC - CO HAS NOT RECEIVED NOTICE OF A PARAGRAPH IV CERTIFICATION WITH RESPECT TO ANDA FILING FOR CO'S CABOMETYX(REG) TABLETS.EXELIXIS INC - EXELIXIS INTENDS TO ENFORCE ITS INTELLECTUAL PROPERTY RIGHTS RELATING TO CABOMETYX.  Full Article

Exelixis Posts Q2 Earnings Per Share Of $0.25
Thursday, 1 Aug 2019 

July 31 (Reuters) - Exelixis Inc ::EXELIXIS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 NON-GAAP EARNINGS PER SHARE $0.29.Q2 GAAP EARNINGS PER SHARE $0.25.Q2 REVENUE $240.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $227.8 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $0.24 -- REFINITIV IBES DATA.UPDATES FINANCIAL GUIDANCE FOR FULL YEAR 2019.SEES 2019 COST OF GOODS SOLD IS EXPECTED TO BE BETWEEN 4% AND 5% OF NET PRODUCT REVENUES.SEES 2019 RESEARCH AND DEVELOPMENT EXPENSES TO BE BETWEEN $330 MILLION AND $350 MILLION.SEES 2019 SELLING, GENERAL AND ADMINISTRATIVE EXPENSES TO BE BETWEEN $220 MILLION AND $240 MILLION.  Full Article

Exelixis And Aurigene Enter Into Exclusive Collaboration
Thursday, 1 Aug 2019 

July 31 (Reuters) - Exelixis Inc ::EXELIXIS AND AURIGENE ENTER INTO EXCLUSIVE COLLABORATION, OPTION AND LICENSE AGREEMENT TO DISCOVER AND DEVELOP NOVEL THERAPIES FOR CANCER.EXELIXIS INC - COMPANIES WILL PARTNER TO ADVANCE SMALL MOLECULES IN UP TO SIX DISCRETE PROJECTS.EXELIXIS INC - WILL MAKE AN UPFRONT PAYMENT OF $10 MILLION FOR EXCLUSIVE OPTIONS TO LICENSE THREE PREEXISTING PROGRAMS FROM AURIGENE.EXELIXIS INC - WILL ALSO CONTRIBUTE RESEARCH FUNDING TO AURIGENE TO FACILITATE DISCOVERY AND PRECLINICAL DEVELOPMENT WORK ON ALL SIX PROGRAMS.EXELIXIS INC - AURIGENE RETAINS LIMITED DEVELOPMENT AND COMMERCIAL RIGHTS FOR INDIA AND RUSSIA.  Full Article

Exelixis Updates Phase 1b Cosmic-021 Trial Of Cabozantinib In Combination With Atezolizumab In Patients With Advanced Solid Tumors
Monday, 15 Jul 2019 

July 15 (Reuters) - Exelixis Inc ::EXELIXIS UPDATES PHASE 1B COSMIC-021 TRIAL OF CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS.EXELIXIS INC - FOUR COHORTS ADDED FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER BASED ON ENCOURAGING EARLY DATA.EXELIXIS INC - ORIGINAL METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND IMMUNOTHERAPY-REFRACTORY NON-SMALL CELL LUNG CANCER COHORTS EXPANDED TO 80 SUBJECTS.  Full Article

Exelixis Says No New Safety Signals Were Identified With Combination Of Cobimetinib And Atezolizumab
Friday, 21 Jun 2019 

June 20 (Reuters) - Exelixis Inc ::EXELIXIS - ON JUNE 19 INFORMED BY GENENTECH, IMSPIRE170, PHASE 3 TRIAL EVALUATING COMBINATION OF COBIMETINIB & ATEZOLIZUMAB DID NOT MEET PRIMARY ENDPOINT.EXELIXIS - IMSPIRE170 SHOWED COMBINATION OF COBIMETINIB & ATEZOLIZUMAB DID NOT REDUCE RISK OF DISEASE PROGRESSION OR DEATH COMPARED TO PEMBROLIZUMAB.EXELIXIS INC - SAFETY PROFILE OBSERVED IN TRIAL WAS CONSISTENT WITH KNOWN SAFETY PROFILES OF INDIVIDUAL MEDICINES.EXELIXIS INC - NO NEW SAFETY SIGNALS WERE IDENTIFIED WITH COMBINATION OF COBIMETINIB AND ATEZOLIZUMAB.EXELIXIS INC - GENENTECH INFORMED EXELIXIS THAT GENENTECH INTENDS TO PRESENT RESULTS FROM TRIAL AT AN UPCOMING MEDICAL MEETING.  Full Article

Exelixis And Iconic Therapeutics Enter Into Exclusive Option And License Agreement For Novel Antibody-Drug Conjugate Program
Thursday, 16 May 2019 

May 16 (Reuters) - Exelixis Inc ::EXELIXIS AND ICONIC THERAPEUTICS ENTER INTO EXCLUSIVE OPTION AND LICENSE AGREEMENT FOR NOVEL ANTIBODY-DRUG CONJUGATE PROGRAM.EXELIXIS INC - ICON-2 PROGRAM TARGETS TISSUE FACTOR (TF) WITH POTENTIAL BROAD IMPACT IN ONCOLOGY.EXELIXIS INC - EXELIXIS WILL MAKE UPFRONT PAYMENT AND CONTRIBUTE RESEARCH FUNDING FOR OPTION TO IN-LICENSE AT INVESTIGATIONAL NEW DRUG (IND) FILING.EXELIXIS INC - WILL GAIN AN OPTION TO LICENSE ICON-2, ICONIC'S LEAD ONCOLOGY ADC PROGRAM, IN EXCHANGE FOR AN UPFRONT OPTION PAYMENT OF $7.5 MILLION.  Full Article

Exelixis Says CEO Michael M. Morrissey's 2018 Total Compensation Was $8 Mln Vs $9.4 Mln In 2017
Thursday, 11 Apr 2019 

April 11 (Reuters) - Exelixis Inc ::EXELIXIS INC SAYS CEO MICHAEL M. MORRISSEY'S 2018 TOTAL COMPENSATION WAS $8 MILLION VERSUS $9.4 MILLION IN 2017 – SEC FILING.EXELIXIS INC - CEO TO MEDIAN EMPLOYEE PAY RATIO FOR FISCAL 2018 WAS 32 TO 1.  Full Article

Exelixis And Ipsen Initiate Phase 3 Pivotal Trial Of Cabozantinib
Wednesday, 5 Dec 2018 

Dec 5 (Reuters) - IPSEN SA ::EXELIXIS AND IPSEN INITIATE PHASE 3 PIVOTAL TRIAL (COSMIC-312) OF CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB VERSUS SORAFENIB IN PREVIOUSLY UNTREATED ADVANCED HEPATOCELLULAR CARCINOMA.  Full Article

Exelixis' Partner Ipsen Receives European Commission Approval Of Cabometyx Tablets
Thursday, 15 Nov 2018 

Nov 15 (Reuters) - Exelixis Inc ::EXELIXIS’ PARTNER IPSEN RECEIVES EUROPEAN COMMISSION APPROVAL FOR CABOMETYX® (CABOZANTINIB) TABLETS FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN ADULTS PREVIOUSLY TREATED WITH SORAFENIB.UNDER TERMS OF COLLABORATION AGREEMENT WITH IPSEN, EXELIXIS WILL RECEIVE A MILESTONE PAYMENT OF $40 MILLION FOR EUROPEAN COMMISSION APPROVAL.PAYMENT WILL BE PAID BY IPSEN WITHIN NEXT 70 DAYS.  Full Article

Exelixis Announces Q3 Earnings Per Share $0.41
Friday, 2 Nov 2018 

Nov 1 (Reuters) - Exelixis Inc ::EXELIXIS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 EARNINGS PER SHARE $0.41.Q3 REVENUE $225.4 MILLION VERSUS $152.5 MILLION.Q3 REVENUE VIEW $172.6 MILLION -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $0.19 -- THOMSON REUTERS I/B/E/S.SEES 2018 TOTAL COSTS AND OPERATING EXPENSES BETWEEN $410 MILLION AND $420 MILLION.  Full Article